Why Immatics N.V.’s (IMTX) Stock Is Down 9.55%
As of Thursday, November 05, Immatics N.V.’s IMTX share price has dipped by 9.55%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna’s PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Commentary & Analysis
Why Immatics N.V.’s (IMTX) Stock Is Down 6.57%
As of Friday, October 30, Immatics N.V.’s IMTX share price has dipped by 6.57%, which has investors questioning if this is right time to buy.Michael Rose
Why Immatics N.V.’s (IMTX) Stock Is Up 5.39%
As of Tuesday, October 20, Immatics N.V.’s IMTX share price has surged by 5.39%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Immatics N.V.’s (IMTX) Stock Is Down 5.57%
As of Friday, October 02, Immatics N.V.’s IMTX share price has dipped by 5.57%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Immatics N.V.’s (IMTX) Stock Is Up 5.02%
As of Wednesday, September 30, Immatics N.V.’s IMTX share price has surged by 5.02%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | IMTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $843.4 | $214.3 | 44% |
|
| Shares Out (Mil) | 156.2 | 53.9 | 71% |
|
| Institutional Ownership | 92.4% | 92.9% | 61% |
|
| Float (Mil) | 70.1 | 41.4 | 54% |
|
| Beta | 1.33 | 0.96 | 77% |
|
| Avg Daily Volume (000s) | 1,160 | 506 | 71% |
|
| Price Change (52-week) |
(33.3%) | 43.9% | 28% |
|
| Growth | IMTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.2% | 13.2% | 51% |
|
| Net Income (5yr) | 2.2% | (10.1%) | 43% |
|
| EPS (5yr) | 18.9% | 15.8% | 66 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.3%) | (15.7%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.496) | ($2.037) | ($2.004) | |
| Month Ago EPS | ($0.504) | ($2.070) | ($2.068) | |
| # Rev Up | 3 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.490) | ($1.904) | ($1.901) | |
| Year/Year Chg | (5.7%) | 7.8% | (6.6%) | |
| Financials | IMTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $48 | $37 | 19% |
|
| Net Income (TTM) (Mil) | ($236) | ($44) | 6% |
|
| EPS (TTM) | ($1.823) | ($1.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($235) | ($34) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($25) | $1 | 25% |
|
| Long-Term Debt (Q1) (Mil) | $14 | $4 | 30% |
|
| Enterprise Value (Q1) (Mil) | $741 | $172 | 38% |
|
| Valuation | IMTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.85 | 2.00 | 52% |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | IMTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (423.7%) | 67.3% | 0% |
|
| Net Margin | (495.3%) | (63.5%) | 2% |
|
| ROA | (38.6%) | (47.5%) | 14% |
|
| ROE | (47.1%) | (53.3%) | 16% |
|
| Liabilities to Assets | 17.7% | 29.6% | 11% |
|
| F-Score | 2 | 2 | 7% |
|
Immatics N.V. did not pass any screens on 11/5/2026.
